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Abstract
Objective: To study the pattern of small B cell lymphomas in Pakistan.
Methods: This descriptive study was carried out at the Aga Khan University Hospital pathology department
including 1721 cases of Non-Hodgkins Lymphoma (NHL) diagnosed during a period of five years (1998-2002)
and classified according to REAL/WHO classification. The antibodies used included Leukocyte Common Antigen
(LCA), Pan B (CD20, CD79a), Pan T (UCHL-1), Bcl 2, Mib 1(Ki 67) and Cyclin D1 (Dako, Denmark).
Results: Out of the 1721 NHL cases, only 140 (8.1%) could be categorized as small B-cell NHL. The study group
comprised small lymphocytic lymphoma/chronic lymphocytic leukemia (58 cases; 41.4%) followed by follicular
lymphoma (46 cases; 32.9%), mantle cell lymphoma (15 cases; 10.7%), extra nodal marginal zone B cell lym-
phoma of MALT type (15 cases; 10.7%), lymphoplasmacytic lymphoma (5 cases; 3.6%) and splenic marginal
zone B-cell lymphoma (1 case; 0.7%). No case of nodal marginal zone lymphoma was diagnosed.
The age ranged from 18 to 98 years with a mean and median of 54.64 and 58.50 years respectively. Small B-
cell NHL was more common in males; with male to female ratio of 2.1. Majority of the small B-cell NHL were
nodal at presentation with a nodal to extranodal ratio of 3.4.
Conclusion: It is concluded that the frequency of these small B-cell NHL is very low in our population in con-
trast to the western literature. Further studies based on epidemiologic and etiological factors are required to look
into this marked difference of occurrence of these indolent lymphomas (JPMA 56:22;2006).
Introduction
In 1994, the International Lymphoma Study Group
proposed a Revised European American Lymphoma
(REAL) classification for lymphoid neoplasm. This classi-
fication system was developed because new lymphoid dis-
ease entities were recognized that were not part of the
National Cancer Institute (NCI) Working Formulation (WF)
and there was a growing need to develop a common classi-
fication system that could be used internationally.1
The REAL classification and the derived World
Health Organization (WHO) classification are structured to 
mirror normal B/T cell differentiation.2 In these modern
classifications distinct disease entities are defined based on
the combination of morphology, immunological and molec-
ular techniques and clinical features.2,3 As defined in the
proposed WHO classification of neoplastic diseases of the
hematopoietic and lymphoid tissues, the small B cell lym-
phomas include B cell small lymphocytic lymphoma/chron-
ic lymphocytic leukemia (SLL/CLL), mantle cell lym-
phoma (MCL), follicular lymphoma (FL), lymphoplasma-
cytic lymphoma (LPL), extra nodal marginal zone B cell
lymphoma of MALT type (MALT-L), nodal marginal zone
B-cell lymphoma (NMZL), and splenic marginal zone B-
cell lymphoma (SMZL). 
The ability to diagnose and distinguish the types of
small B-cell lymphoid neoplasms is extremely important
because of differences in presentation, treatment options,
clinical course and prognosis. The small B cell lymphomas
are among the best examples of how malignant lymphomas
can be related to the normal immune system.4
Immunophenotypic analysis is critical in categorizing small
B-cell neoplasms and numerous paraffin-reactive antibodies
are available for differentiating these neoplasms.5-7
The WHO has made a conceptual grouping of non
Hodgkin's lymphoma (NHL) into four categories (indolent,
aggressive, highly aggressive and localized indolent).
Except extra marginal zone B-cell lymphoma of MALT
type all other small B-cell lymphomas are grouped as indo-
lent lymphomas. Mostly these are diseases of older adults,
almost always above the age of 40 years. Extra nodal mar-
ginal zone MALT type is grouped in the localized indolent
lymphomas and occur at any age.8 One study showed that
these indolent lymphomas represent 40-50% of all NHL.9
As a group small cell NHLs are relatively uncommon in
Pakistan and are therefore not widely studied particularly
according to the guidelines of REAL/WHO classification.10-
13
The objective of this study is to determine the pattern
of small B cell lymphomas in Pakistan.
Patients and Methods
This descriptive study was carried out at the Aga
Khan University Hospital (AKUH) pathology department.
The study included 1721 cases of Non-Hodgkin lymphoma
(NHL) which were diagnosed in the section of histopathol-
ogy during a five years period (1998-2002). 
The pathology department receives surgical speci-
mens from the AKUH in Karachi and through 65 pathology
laboratory collection points in Pakistan. It covers a large
geographical area, with collection points located in all
major cities like Karachi, Hyderabad, Multan, Lahore,
Quetta, Peshawar, Islamabad, Rawalpindi, Larkana and also
many rural locations. Quality control for diagnostic pathol-
ogy at AKUH is maintained through internal and external
quality checks. External quality assurances for diagnostic
pathology are maintained by the College of American
Pathologists (CAP) surveys. Internal quality assurances are
maintained by the use of histochemical stains and immuno-
histochemical techniques. Biological markers are used for
malignancies, which necessitated cellular typing and sub-
typing. The departmental consensus committee confirms the
diagnosis. 
All specimens for the present study were grossed,
processed and initially evaluated on Hematoxylin and Eosin
(H&E) stained sections. Subsequently immunohistochemi-
cal analysis was performed by employing envision tech-
nique. The antibodies used in immunohistochemical stain-
ing included Leukocyte Common Antigen (LCA), Pan B
(CD20, CD79a), Pan T (UCHL-1), Bcl 2, Mib 1(Ki 67) and
Cyclin D1 (Dako, Denmark). Parallel positive and negative
controls were always run with each new batch of staining. 
All the cases were characterized on the basis of mor-
phology and immunohistochemical features and classified
according to REAL/WHO classification of lymphoid neo-
plasms. The following entities were recognized, small lym-
phocytic lymphoma/leukemia (SLL/CLL), follicular lym-
phoma (FL), mantle cell lymphoma (MCL), extra nodal
marginal zone B-cell lymphoma of MALT type (MALT-L),
lymphoplasmacytic lymphoma (LPL), nodal marginal zone
B-cell lymphoma (NMZL) and splenic marginal zone B-cell
lymphoma (SMZL).
Demographic variables recorded were the hospital
patient-number, date, name, age, sex, address, topography,
morphology, and grading. The cases were categorized by
tumor site, age and sex of the patient. The data obtained was
analyzed using SPSS version 12.5.
Results
A total of 1721 NHLs were diagnosed during the
study period of five years (1998-2002) according to
REAL/WHO classification and out of these only 140 (8.1%)
were in the category of small B-cell NHL. The study group
comprised SLL/CLL (58 cases; 41.4%) followed by FL (46
cases; 32.9%), MCL (15 cases; 10.7%), MALT-L (15 cases;
10.7%), LPL (5 cases; 3.6%) and SMZL (1 case; 0.7%). No
case of nodal marginal zone lymphoma was diagnosed
(Table 1).
The age ranged from 18 to 98 years with mean and
median of 54.64 and 58.50 years respectively. As a group
small B-cell NHL were more common in males as com-
pared to females; with male to female ratio of 2.1. Majority
of small B-cell NHL were nodal at presentation with a nodal
to extranodal ratio of 3.4. In 8 cases site of biopsy was not
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mentioned in the clinical data (Table 1).
SLL/CLL, FC, LPL, and MCL more commonly
involved the lymph nodes at the time of presentation.  Most
common extranodal NHL category was MALT-L. Salivary
gland (7 cases) was the commonest site of involvement fol-
lowed by gastrointestinal tract (5 cases), thyroid (1 case), lid
(1 case), and nasopharnyx (1 case).
SLL/CLL accounted for 41.4% of small B-cell NHL
and 3.4% of all NHL in our study. The mean and median
ages were 57.3 and 60 years respectively. It showed male
dominance with a M/F ratio of 3.8:1. FL was the second
commonest small B-cell NHL and accounted for 32.9% of
small B-cell NHL and 2.6% of all NHL. The mean and
median ages were 54.2 and 56.0 years respectively with
M/F ratio of 1.1:1. (Table 2) Majority of FL were grade II
(45.6%) followed by grade I (34.7%) and grade III (19.5%).
MCL and MALT lymphomas each accounted for a
similar number of cases in our study, 10.7% of small B-cell
NHL and 0.87% of all NHL. The mean and median ages of
MCL were 51.8 and 55 years respectively and of MALT
lymphoma, 46.3 and 45 years respectively. Both showed a
male dominance with the M/F ratio of 4:1 and 2.7:1 for the
MCL and MALT lymphoma respectively. In our study there
were only 5 cases of LPL which accounted for 3.6% of
small B-cell NHL and 0.29% of all NHL, mean and median
ages were 59.4 and 65 years with M/F ratio of 1:1.5
(Tables 1 and 2).
Discussion
Small B-cell NHL are derived from the B-lympho-
cyte and represent a heterogeneous group of diseases in
terms of clinical, pathological and molecular aspects.14
These lymphomas have been included in the low-grade cat-
egory by pathologists, and indeed, these patients do present
a disease that is initially indolent.15
The incidence of lymphoma is increasing worldwide
largely contributed by NHL.15 According to Karachi
(South) Cancer Registry (1995-1999) NHL is the 9th most
common malignancy among males in Karachi and ranked
10th among the females.16,17 In Pakistan no comprehensive
data is available about the frequency of small B-cells NHL.
In the present study, 140 cases of small B-cell NHL were
diagnosed over a period of five years according to
WHO/REAL classification by using histological as well as
immunohistochemical studies. As a group small B cell lym-
phomas accounted for 8.1% of NHLs. In contrast to this,
however the western studies show much higher incidence of
small B-cell lymphomas.
In this study, among the small B-cell NHL,
SLL/CLL accounted for the largest group and it was 3.3%
of all NHL. This does not correlate with western data which
shows it to be 6.7% amongst all NHL according to the NHL
classification Project data.18 The second commonest small
B-cell non-Hodgkin's lymphoma in our study was Follicular
lymphoma and it was 2.6% of all NHL. This is again in con-
trast to western data accounting for 25-30% of all NHLs in
the USA14, FL are also uncommon in other developing
countries and reported incidence in various series from
other parts of Asia ranged from 3.4% to 13%.10,19
Table 1. Frequencies of Small B- cell lymphomas.
Diagnosis Number Percent of Percent of Nodal NHL Extranodal Site not mentioned
of Cases small B-NHL all NHL
(n=140) (n=1721) n(%) NHLn(%) n(%)
SLL/CLL 58 41.1 3.37 45(77.5) 7(12.0) 6 (10.3)
FL 46 33.0 02.6 40(86.9) 5(10.8) 1 (2.1)
MALT-L 15 10.8 0.87 - 15(100) -
MCL 15 10.8 0.87 13(86.6) 1(06.6) 1 (6.6)
LPL 05 03.6 0.29 04(80.0) 1(20.0) - 
SMZL 01 00.7 0.06 - 1(100) -
Total 140 100.0 8.06 102(72.8) 30(21.4) 8 (5.7)
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Table 2. Age and sex distribution of Small B-cell lymphomas.
Diagnosis Number Mean (years) Standard MIE Ratio
of cases deviation
SLL/CLL 58 57.31 12.299 3.8:1
FL 46 54.26 15.538 1.1:1
MCL 15 51.87 15.896 4:1
MALT 15 46.33 14.994 2.7:1
LPL 05 59.40 20.959 1:1.5
SMZL 01 57.31 - -
The median ages of SLL/CLL, FL, MCL, MALT-L,
LPL and SMZL in our study correlate with the median ages
given in literature.18, 20
NHL is more common in males however there is sig-
nificant difference in the male to female ratio in various
series. Data from developed countries report a male to
female ratio of 1.4:1 while from developing countries the
ratio ranges from 4.5 to 3.1.10,21 In small B-cell NHL
SLL/CLL, MCL and LPL are also more common subcate-
gories in males. However FL and MALT-L have slightly
female preponderance.18 Analysis of our data revealed that
small B-cell NHL are more common in males.
In the present study, majority of small B-cell NHL
were nodal at presentation with the nodal to extranodal ratio
of 3.4 and this is similar to another study that showed 20%
as primary extranodal NHL.22 In extranodal lymphomas, in
the present study 50.0% were MALT-L. This also does not
correlate with the western data which shows 8% of all
NHL.23 We found that salivary gland was the commonest
site of presentation in MALT-L where as in literature, gas-
trointestinal tract represents the most common site.14,15 
Low and intermediate-grade lymphomas including
small B-cell NHL are not AIDS-associated and we had
expected a higher component of this neoplasm in our series,
considering the low prevalence of HIV/AIDS.24,25
Biological studies are required to determine the cause of a
higher component of aggressive NHL in our population in
comparison to the low grade NHL.
We conclude that the frequency of these small B-cell
NHL is very low in our population, in sharp contrast to the
western literature. Further studies are required to look into
this marked difference of occurrence of these indolent lym-
phomas.
References
1. Fisher RI, Miller TP, Grogan TM. New REAL clinical entities. Cancer J Sci
Am 1998;4:S5-12.
2. Ottensmeier C. The classification of lymphomas and leukemia's. Chem Bio
Interact 2001;135-136:653-64.
3. Mourad WA, Tulbah A, Shoukri M, Al-Dayel F, Akhtar M, Ali MA, et al.
Primary diagnosis and REAL/WHO classification of non-Hodgkin's lym-
phoma by fine-needle aspiration: cytomorphologic and  mmunophenotypic
approach. Diagn Cytopathol 2003;28:191-5.
4. Swerdlow SH. Small B cell lymphomas of the lymph nodes and spleen: prac-
tical insights to diagnosis and pathogenesis. Mod Pathol 1999;12:125-40.
5. Chen CC, Raikow RB, Sonmez AE, Swerdlow SH. Classification of small B-
cell lymphoid neoplasms using a paraffin section immunohistochemical
panel. Appl Immunohistochem Mol Morphol 2000;8:1-11.
6. Kurtin PJ, Hobday KS, Ziesmer S, Caron BL. Demonstration of distinct anti-
genic profiles of small B-cell lymphomas by paraffin section immunohisto-
chemistry. Am J Clin Pathol 1999;112:319-29.
7. Xu Y, McKenna RW, Asplund SL, Kroft SH. Comparision of immunopheno-
types of small B-cell neoplasms in primary lymph node and concurrent blood
or bone marrow samples. Am J Clin Pathol 2002;118:      758-64.
8. Chan, JK. The new World Health Organization classification of lymphomas:
the past, the present and the future. Hematol-Oncol 2001;19:129-50. 
9. Solal Celigny P. Management of histologically indolent non-Hodgkin's
lymphomas. Baillieres Clin Haematol 1996;9:669-87.
10. Aziz, Z, Rehman A, Akram M, Saeed A. Non-Hodgkin's lymphoma in
Pakistan: a clinicopathological profile of 175 patients. J Pak Med Assoc
1999;49:11-15.
11. Muzaffar S, Pervez S,  Aijaz F, Aziz SA, Hasan SH. Immunophenotypic
analysis of non-Hodgkin's lymphoma. J Pak Med Assoc 1997;47:106-9.
12. Khan M.S, Ahmad M, Mushtaq S. Immunophenotypes of non hodgkin's lym-
phoma: A study of 100 cases in Pakistan. Pak Armed Forces Med J 1993;43:5-
12.
13. Shah SH, Muzaffar S, Pervez S, Aziz SA, Hasan SH. Childhood non
Hodgkin's  lymphoma: An immunophenotypic  analysis. J Pak Med Assoc
2000;50:89-91.
14. Souberyan I, de Mascarel AD. Small B-cell Lymphoproliferative disorders: an
overview of diagnostic approach. Crit-Review-Oncol-Hematol 2000;35:3-11.
15. Berger F, Felman P, Sonet A, Salles G, Bastion Y, Bryon PA, et al.
Nonfollicular small B-cell Lymphomas: a heterogenous group of patients with
distinct clinical features and outcome. Blood 1994;83:2829-35.
16. Yaqoob N, Noorali S, Nasir MI, Pervez S. Non-Hodgkin's  lymphoma present-
ing as cutaneous lesions. JCPSP 2003;13:29-32.
17. Bhurgri Y. Epidemiology of cancers in Karachi (1995-1999). Pharmacia
Upjohn.
18. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization
Classification of Tumours .Pathology and Genetics of Tumours of
Heamatopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
19. Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-
Hodgkin's lymphoma in India: a study of 2773 Lymphomas using REAL and
WHO Classification. Ann-Oncol.2000;11suppl 1:63-7.
20. Anon. A clinical evaluation of the international Lymphoma Study Group
Classification of non-Hodgkin's lymphoma. 'The Non-Hodgkin's lymphoma
Classification Project'. Blood 1997;89:3909-18.
21. Abrar A, Sadaqat AG. Non-Hodgkin's lymphoma in South Punjab
Retrospective analysis of 148 patients. Pak J Med Res 1989;28:223-31.
22. Krol AD, Ie-Cessie S, Snijder S, KIluin-Nelemans JC, Kluin PM, Noordijk
EM. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of
alternative definitions tested in the Comprehensive Cancer Centre West pop-
ulation-based NHL registry. Ann-Oncol 2003;14:131-9. 
23. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT Lymphomas.
Hematology (Am-Soc-Hematol-Educ-Program) 2001;241-58.
24. Baqi S, Kayani N, Khan JA. Epidemiology and clinical profile of HIV/AIDS
in Pakistan. Trop Doct 1999;29:144-8.
25. Biggar RJ AIDS-related cancers in the era of highly active antiretroviral ther-
apy. Oncology 2001;15:439-49.
Vol. 56, No. 1, January 2006 25
